Bevacizumab Bevatas 100mg - Anticancer drugs | Intas | MHP
BEVATAS
 |
RENAL CELL CARCINOMA |
DESCRIPTION
Bevacizumab is a drug sold under the name of Bevatas 400mg and which is categorized as monoclonal anti-body & anti-angiogenesis
When Bevatas concomitant use with human monoclonal antibody IgG1, that circumstance and prohibits the biological action of human vascular endothelial growth factor (VEGF)
USAGE
Bevatas 400mg is indicated for the treatment of some of the conditions like Metastatic colon or rectal cancer Non-squamous, non-small cell lung cancer Glioblastoma Metastatic renal cell cancer Metastatic cervical cancer Epithelial ovarian, fallopian tube or peritoneal cancerMECHANISM OF ACTION
Bevatas 400mg Injection comprises an active compound like Bevacizumab which binds to VEGF and avoid the communication of VEGF to its receptors like Flt-1 & KDR) present on the surface of the cells This interaction prevents endothelial cell multiplication and new blood vessel production occurs Hence in counts cessation of metastatic cancer cells development happens
 |
BEVATAS |
Brand : Bevatas
Ingredients : Bevacizumab
Strength : 400mg/16ml & 100mg/4ml
Manufactured :Intas Pharmaceuticals
Package :400mg of Bevacizumab containing vial
Distribution:
The volume of distribution is 2.9 (22%) LElimination
The Bevacizumab half life period is 20days (11 to 50days)
DOSAGE MANAGEMENT
KEY POINT
Avoid administration of Bevatas 400mg Injection before at least 28 days following surgery and the wound is completely curedMETASTATIC COLORECTAL CARCINOMA
Concomitant use with 5-fluorouracil based chemotherapy is the usual dosage of Bevatas : While concomitant use with bolus IFL the dose is 5mg/kg of Bevatas for every 2 weeks IV. While in combination with FOLFOX4 the dose is 10mg/kg ofBevatas for every 2 weeks IV 5mg/kg IV Bevatas for every 2 weeks or 7.5 mg/kg Bevatas as IV every 3 weeks by concurrently used with fluoropyrimidine Irinotecan or fluoropyrimidine oxaliplatin based therapyNON-SMALL CELL LUNG CANCER
While combining with carboplatin and paclitaxel : The Bevatas usual dosage is 15mg/kg IV for every 3 weeks byGLIOBLASTOMA
For every 2 weeks : 10mg/kg of Bevatasadministered IVMETASTATIC CERVICAL CANCER
Combining with paclitaxel and cisplatin or with paclitaxel and topotecan : The drug Bevatas usual dosage is 15mg/kg of Bevatas given intravenously for every 3 weeks
METASTATIC RENAL CELL CANCER
Concurrent use with interferon alfa : The Bevatasusual dosage is 10mg/kg IV for every 2 weeksEPITHELIAL OVARIAN, FALLOPIAN TUBE OR PERITONEAL CANCER
Platinum opposing: Concurrent use with paclitaxel, pegylated liposomal doxorubicin or topotecan :The Bevatas regular dosage is 10mg/kg of Bevatas for every 2 weeks Or Combining with topotecan : The Bevatas regular dosage 15mg/kg ofBevatas given through IV for every 3 weeks Platinum responsive concomitant with carboplatin and paclitaxel for 6 to 8 cycles : The drug Bevatasrecommended dosage of is 15mg/kg given IV for 3 weeks Combining with gemcitabine & carboplatin for 6 to 10 cycles : The Bevatas recommended dosage is 15mg/kg of Bevatas given IV for 3 weeksPREPARATION & ADMINISTRATION
Bevatas is intravenous solution At initial infusion: given IV infusion over 90 minutes Following infusions: give second infusion over 60 minutes, if tolerated Administer all following infusion over 30minutes Bevatas IV infusion is prepared in aseptic condition Bevatas 400mg containing 16ml solution whereas 100mg containing 4ml Bevatasdilute into 100ml of 0.9% NS Do not dilute with dextrose solution Dispose the remaining portion of medicine which is left in a vial
FOR FURTHER INFORMATION
MOBILE NO : +91-9940472902EMAIL : millionhealthpharmaceuticals@gmail.com
WEBSITE URL : https://millionpharma.com/bevatas.php
Comments
Post a Comment